Area of research
Cardiology and Cardiovascular Medicine · Economics and Econometrics
Research interest
Research focused on Clinical trial and Percutaneous coronary intervention, with related work in hERG, Food and drug administration, Heart failure. Notable publications include 'Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention', '2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials', and 'Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk'.
Development of Imaging Endpoints for Clinical Trials in AL and ATTR Amyloidosis
Patient-Reported Outcome Measures and Patient Engagement in Heart Failure Clinical Trials: Multi-Stakeholder Perspectives
Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative—Group 3 pulmonary hypertension
Functional and Symptomatic Clinical Trial Endpoints
Optimizing the Design and Analysis of Future AKI Trials
Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium
Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel from the Heart Failure Collaboratory and Academic Research Consortium
Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI
Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention
Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk
General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA <i>In Silico</i> Strategy
Clinical and regulatory landscape for cardiogenic shock: A report from the Cardiac Safety Research Consortium ThinkTank on cardiogenic shock
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
Clinical trial design and new therapies for pulmonary arterial hypertension
Heart Failure With Preserved Ejection Fraction Expert Panel Report
Assessment of Multi‐Ion Channel Block in a Phase I Randomized Study Design: Results of the Ci<scp>PA</scp> Phase I <scp>ECG</scp> Biomarker Validation Study
Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes
Drug‐induced Proarrhythmia and Torsade de Pointes: A Primer for Students and Practitioners of Medicine and Pharmacy
Mechanistic Model‐Informed Proarrhythmic Risk Assessment of Drugs: Review of the “CiPA” Initiative and Design of a Prospective Clinical Validation Study
Enhancing Insights into Pulmonary Vascular Disease Through a Precision Medicine Approach. A Joint NHLBI–Cardiovascular Medical Research and Education Fund Workshop Report
Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints
Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants?
Evolution of strategies to improve preclinical cardiac safety testing
New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval
The Cardiac Safety Research Consortium enters its second decade: An invitation to participate
Results From the IQ‐CSRC Prospective Study Support Replacement of the Thorough QT Study by QT Assessment in the Early Clinical Phase
Late sodium current block for drug‐induced long QT syndrome: Results from a prospective clinical trial
Comprehensive T wave Morphology Assessment in a Randomized Clinical Study of Dofetilide, Quinidine, Ranolazine, and Verapamil
Implications of the IQ-CSRC Prospective Study: Time to Revise ICH E14